keyword
MENU ▼
Read by QxMD icon Read
search

Side effects hydroxychloroquine

keyword
https://www.readbyqxmd.com/read/29040457/treatment-of-chronic-q-fever-clinical-efficacy-and-toxicity-of-antibiotic-regimens
#1
S E van Roeden, C P Bleeker-Rovers, M J A de Regt, L M Kampschreur, A I M Hoepelman, P C Wever, J J Oosterheert
Background: Evidence on effectivity of first line treatment for chronic Q fever, tetracyclines (TET) plus hydroxychloroquine (HCQ), and potential alternatives is scarce. Methods: We performed a retrospective, observational cohort study to assess efficacy of treatment with TET plus quinolones (QNL), TET plus QNL plus HCQ, QNL monotherapy or TET monotherapy compared to TET plus HCQ in chronic Q fever patients. We used a time-dependent Cox proportional hazards model to assess our primary (all-cause mortality) and secondary outcomes (first disease-related event and therapy failure)...
October 10, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29026363/highly-accelerated-onset-of-hydroxychloroquine-macular-retinopathy
#2
Ethan M Stern, Jordan S Johnson, Donald A Mazzulla
BACKGROUND: Hydroxychloroquine (HCQ, Plaquenil) is often prescribed in lieu of other sulfate antimalarials to treat rheumatologic diseases because of its pharmacologic efficacy and few reported side effects. However, a known potential side effect of HCQ is retinal toxicity. CASE REPORT: A 61-year-old black female presented for screening of ophthalmic disease 2 months after initiation of HCQ for the treatment of polyarthralgia with a positive rheumatoid factor. At the time of the examination, she had taken a cumulative total of 19...
2017: Ochsner Journal
https://www.readbyqxmd.com/read/28992797/hydroxychloroquine-desensitization-an-effective-method-to-overcome-hypersensitivity-a-multicenter-experience
#3
Y Tal, R Maoz Segal, P Langevitz, S Kivity, Z Darnizki, N Agmon-Levin
Hydroxychloroquine (HCQ) is widely used to treat autoimmune/rheumatic diseases such as systemic lupus erythematosus (SLE). The immune modulation effects of HCQ have been highlighted as beneficial for maintaining remission of SLE as well as ameliorating skin, joint and other manifestations. Moreover, HCQ exposure for prolonged periods as well as during pregnancy is considered safe, therefore it is recommended for the vast majority of SLE patients. Although HCQ therapy requires follow-up by a specialist, its most common side effects are mild gastrointestinal disturbances, sensitivity to light and skin rashes...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/28906353/immunomodulatory-treatments-for-persistent-and-chronic-immune-thrombocytopenic-purpura-a-prisma-compliant-systematic-review-and-meta-analysis-of-28-studies
#4
REVIEW
Emmanuelle Weber, Quitterie Reynaud, Romain Fort, Stéphane Durupt, Pascal Cathébras, Isabelle Durieu, Jean-Christophe Lega
BACKGROUND: Corticosteroid sparing is required in 15% to 40% of adults with persistent or chronic primary immune thrombocytopenic purpura (ITP). Herein, the efficacy of immunomodulatory drugs (dapsone, interferon alpha, danazol, and hydroxychloroquine as second-third-line therapies in ITP is investigated. METHODS: MEDLINE was searched for studies that included patients with persistent or chronic primary ITP and published before the end of December 2014. Two investigators independently extracted data regarding study design, patient characteristics, dosage schedule, time to response, and occurrence of adverse events...
September 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28826825/effect-of-hydroxychloroquine-on-treatment-and-recurrence-of-acute-brucellosis-a-single-blind-randomized-clinical-trial
#5
Mohammad Mahdi Majzoobi, Seyyed Hamid Hashemi, Mojgan Mamani, Fariba Keramat, Jalal Poorolajal, Hamid Reza Ghasemi Basir
Nowadays, one of the major problems of brucellosis is its high recurrence rate and using more than one course of standard treatment regimens. Therefore, more researches need to find more effective treatments which lead to prompt recovery and reduce the relapse of disease. This single-blind randomized study was designed to evaluate the effect of the standard treatment of brucellosis in combination with hydroxychloroquine. Totally, 177 patients with acute brucellosis were randomly assigned to one of two treatment groups including doxycycline-streptomycin (DS) and doxycycline-streptomycin-hydroxychloroquine (DSH)...
August 4, 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28584619/clinical-efficacy-and-safety-of-methotrexate-versus-hydroxychloroquine-in-preventing-lichen-planopilaris-progress-a-randomized-clinical-trial
#6
Farahnaz Fatemi Naeini, Mina Saber, Ali Asilian, Sayed Mohsen Hosseini
BACKGROUND: Lichen planopilaris is an inflammatory cicatricial alopecia, and its management is a challenge for dermatologists. We aimed to compare the efficacy of methotrexate and hydroxychloroquine on refractory lichen planopilaris. METHODS: In a randomized clinical trial, 29 patients were randomly allocated to receive either 15 mg methotrexate/week or 200 mg hydroxychloroquine twice a day for 6 months. Side effects, symptoms/signs, and laboratory tests were assessed periodically...
2017: International Journal of Preventive Medicine
https://www.readbyqxmd.com/read/28386850/therapeutic-approaches-in-clippers
#7
REVIEW
Guillaume Taieb, Thibaut Allou, Pierre Labauge
CLIPPERS for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids, is a steroid-sensitive and steroid-dependent brainstem inflammatory disease of unknown origin. Since its first description in 2010, about 60 cases have been reported throughout the world. The mean age at onset is 50 years and men seem to be more frequently affected. In patients without chronic corticosteroid therapy or immunosuppressive agents, the disease had a relapsing remitting course, and the mean annualized relapse rate was 0...
May 2017: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/28355984/hydroxychloroquine-induced-hyperpigmentation-in-systemic-diseases-prevalence-clinical-features-and-risk-factors-a-cross-sectional-study-of-41-cases
#8
E Bahloul, M Jallouli, S Garbaa, S Marzouk, A Masmoudi, H Turki, Z Bahloul
Introduction Hydroxychloroquine is an antimalarial agent widely prescribed in internal medicine, rheumatology and dermatology. Its use can be complicated by various side effects including skin pigmentation. Objectives The aim of the study is to review epidemiological, clinical features and risk factors of hydroxychloroquine-induced pigmentation. Materials and methods We performed a cross-sectional study conducted over a period of 5 months. During this period, patients who had been treated with hydroxychloroquine for over 6 months, in the internal medicine department, underwent a complete dermatological examination...
October 2017: Lupus
https://www.readbyqxmd.com/read/27927040/hydroxychloroquine-in-systemic-lupus-erythematosus-sle
#9
REVIEW
C Ponticelli, G Moroni
Hydroxychloroquine (HCQ) is an alkalinizing lysosomatropic drug that accumulates in lysosomes where it inhibits some important functions by increasing the pH. HCQ has proved to be effective in a number of autoimmune diseases including systemic lupus erythematosus (SLE). Areas covered: In this review the mechanisms of action, the efficacy, and the safety of HCQ in the management of patients with SLE have been reviewed. HCQ may reduce the risk of flares, allow the reduction of the dosage of steroids, reduce organ damage, and prevent the thrombotic effects of anti-phospholipid antibodies...
March 2017: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27745936/-hydroxychloroquine-induced-hearing-loss-first-case-of-positive-rechallenge-and-analysis-of-the-french-pharmacovigilance-database
#10
J-N Chatelet, M Auffret, S Combret, E Bondon-Guitton, M Lambert, S Gautier
INTRODUCTION: Several cases of hearing loss induced by hydroxychloroquine have been reported in the literature but the role of hydroxychloroquine still remains debated. CASE REPORT: We report the first case, to our knowledge, of hearing loss induced by hydroxychloroquine with a positive re challenge in a woman treated for systemic lupus. An analysis of the French pharmacovigilance database allowed to identify 23 additional cases of hearing loss in patients treated with hydroxychloroquine and, among them, 8 had systemic lupus...
May 2017: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/27708979/hydroxychloroquine-induced-agranulocytosis-in-a-patient-with-long-term-rheumatoid-arthritis
#11
Edward Sames, Heather Paterson, Charles Li
Agranulocytosis is a rare and little-known side effect of hydroxychloroquine use. This report describes the case of a 71-year-old woman with poorly controlled rheumatoid arthritis who developed agranulocytosis after several months of hydroxychloroquine therapy. She had been on several different disease-modifying antirheumatic drugs, including methotrexate and leflunomide, for her rheumatoid arthritis. Treatment became complicated following a diagnosis of leflunomide-induced pulmonary fibrosis that was discovered after an intensive care unit (ICU) admission for severe Pseudomonas pneumonia...
June 2016: European Journal of Rheumatology
https://www.readbyqxmd.com/read/27683152/long-term-efficacy-of-high-doses-of-intravenous-immunoglobulins-in-generalized-scleromyxoedema-case-report
#12
Federica Arginelli, Franco Rongioletti, Giampiero Girolomoni, Giovanni Pellacani, Davide Guardoli, Andrea Conti
Scleromyxoedema is a rare disease with a progressive and disabling course involving dermal deposition of mucin and fibroblast proliferation; it is characterized clinically by a diffuse papular eruption, skin thickening, oedema and decreased skin flexibility, especially of the face and hands. Current therapy options are based on evidence from a limited number of case reports. The clinical manifestations and treatment of a 64-year-old man affected by scleromyxoedema with severe skin involvement of the face, arms and hands, decreased mouth opening and hypomotility of the fingers are reported...
September 2016: Journal of International Medical Research
https://www.readbyqxmd.com/read/27668102/a-unique-case-of-mycophenolate-induced-colitis-after-10-years-of-use
#13
Abhinav Goyal, Moiz Salahuddin, Yogesh Govil
A 31-year-old female with a history of lupus nephritis on Hydroxychloroquine, Prednisone, and Mycophenolate Mofetil (MMF) for 10 years presented to the hospital for ankle swelling. On day four, she started to have severe, nonbloody, watery diarrhea with abdominal distension and tenderness. Stool PCR was negative for C. difficile. CT abdomen/pelvis showed gaseous distension of the colon without any obstruction. Flexible sigmoidoscopy revealed a normal looking mucosa. Histopathology showed crypt atrophy and increased crypt apoptosis, consistent with MMF colitis...
2016: Case Reports in Gastrointestinal Medicine
https://www.readbyqxmd.com/read/27587201/a-review-of-clinical-trials-of-belimumab-in-the-management-of-systemic-lupus-erythematosus
#14
Alexis Garcia, Juan B De Sanctis
There have been few changes over the last 50 years in the treatment of Systemic lupus erythematosus (SLE), using non-specific anti-inflammatory agents such as: nonsteroidal anti-inflammatory drugs along with the immune cell modulating agent hydroxychloroquine for mild disease, and broad spectrum immunosuppressants plus antiinflammatories such as corticosteroids, azathioprine, cyclophosphamide, or mycophenolate during flares or severe disease with organ involvement. In some patients, the response is inadequate and side effects appear from mild unpleasant up to severe toxicity...
2016: Current Pharmaceutical Design
https://www.readbyqxmd.com/read/27263963/relapsed-hydroxychloroquine-induced-thrombocytopenia-in-a-systemic-lupus-erythematosus-patient
#15
Vanesa Antón Vázquez, Luis Pascual, Héctor Corominas, Isabel Giménez Torrecilla
Hydroxychloroquine is used in the long-term therapy of systemic lupus erythematosus (SLE). Although considered to be a safe treatment, side effects have been documented. An uncommon side effect is thrombocytopenia. In order to establish the diagnosis of thrombocytopenia secondary to Hydroxychloroquine, non-pharmacological causes must be ruled out and it is necessary to determine a recurrence after re-exposure to the drug. We present one case of severe thrombocytopenia occurring in a patient with SLE undergoing treatment with Hydroxychloroquine...
September 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/27137831/-the-effect-of-drugs-used-in-treatment-of-skin-disorders-on-visual-system
#16
REVIEW
Beata Szostakiewicz-Grabek, Maria Juszkiewicz-Borowiec, Dorota Krasowska
Drugs with side effects affecting vision are often used in the treatment of skin disorders. The study evaluated principal groups of medicines which may negatively influence vision and the eye itself. Antimalaric drugs may cause a number of disorders of vision and a diagnosed retinophaty is an absolute contraindication. Retinoids often cause a dry eye condition, which results in intolerance to wearing contact lenses. They can also be a cause of poor nightly vision. Psoralens, used in photochemotherapy, can penetrate to the frontal part of the eye, inducing clouding of the lens and cataract...
April 2016: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/27123811/significantly-enhanced-tumor-cellular-and-lysosomal-hydroxychloroquine-delivery-by-smart-liposomes-for-optimal-autophagy-inhibition-and-improved-antitumor-efficiency-with-liposomal-doxorubicin
#17
Yang Wang, Kairong Shi, Li Zhang, Guanlian Hu, Jingyu Wan, Jiajing Tang, Sheng Yin, Jiandong Duan, Ming Qin, Neng Wang, Dandan Xie, Xinle Gao, Huile Gao, Zhirong Zhang, Qin He
Hydroxychloroquine (HCQ) inhibits autophagy and therefore can sensitize some cancer cells to chemotherapy, but the high doses required limit its clinical use. Here we show that loading HCQ into liposomes (HCQ/Lip) decorated with a pH-sensitive TH-RGD targeting peptide (HCQ/Lip-TR) can concentrate HCQ in B16F10 tumor cells and lysosomes. HCQ/Lip-TR was efficiently internalized as a result of its ability to bind ITGAV-ITGB3/integrin αvβ3 receptors highly expressed on the tumor cell surface and to undergo charge reversal from anionic at pH 7...
June 2, 2016: Autophagy
https://www.readbyqxmd.com/read/27088206/-current-view-on-chloroquine-derivative-treatment-from-rheumatologist-perspective-and-possible-ocular-side-effects
#18
REVIEW
Katarzyna Pawlak-Buś, Magdalena Gaca-Wysocka, Andrzej Grzybowski, Piotr Leszczyński
Anti-malarial drugs specifically hydroxychloroquine (HCQ) or chloroquine (CQ) are very effective in treating and preventing the symptoms of systemic lupus erythematosus and other connective tissue diseases. These medications have shown to improve joint and muscle pain and arthritis, skin rashes, fatique, fever and also to control systemic signs of lupus as pericarditis or pleuritis. Shortterm and long-term treatment reduce cholesterol and have anti-platelet effect with decreasing risk of cardiovascular disease...
March 2016: Polski Merkuriusz Lekarski: Organ Polskiego Towarzystwa Lekarskiego
https://www.readbyqxmd.com/read/27049308/hydroxychloroquine-binding-to-cytoplasmic-domain-of-band-3-in-human-erythrocytes-novel-mechanistic-insights-into-drug-structure-efficacy-and-toxicity
#19
Mizuki Nakagawa, Kotomi Sugawara, Tatsufumi Goto, Hideki Wakui, Wataru Nunomura
Hydroxychloroquine (HCQ) is a widely used drug in the treatment of autoimmune diseases, such as arthritis and systemic lupus erythematosus. It has also been prescribed for the treatment of malaria owing to its lower toxicity compared to its closely related compound chloroquine (CQ). However, the mechanisms of action of HCQ in erythrocytes (which bind preferentially this drug) have not been documented and the reasons underlying the lower side effects of HCQ compared to CQ remain unclear. Here we show that, although the activity of erythrocyte lactate dehydrogenase (LDH), but not GAPDH, was inhibited by both HCQ and CQ in vitro, LDH activity in erythrocytes incubated with 20 mM HCQ was not significantly reduced within 5 h in contrast to CQ did...
May 13, 2016: Biochemical and Biophysical Research Communications
https://www.readbyqxmd.com/read/26697765/treating-to-target-in-established-rheumatoid-arthritis-challenges-and-opportunities-in-an-era-of-novel-targeted-therapies-and-biosimilars
#20
REVIEW
Thasia G Woodworth, Alfons A den Broeder
There is increasing consensus that periodic monitoring of disease activity status in rheumatoid arthritis (RA) patients to achieve and maintain remission, or at least low disease activity (LDA), the so-called treat to target (T2T) improves outcomes regardless of the duration of disease. Based on systematic literature reviews (SLRs) of clinical trials and registries, International Recommendations published in 2015 represent expert opinion describing efficacy and safety of conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and biologic DMARDs (bDMARDs)...
August 2015: Best Practice & Research. Clinical Rheumatology
keyword
keyword
26650
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"